Clinigen launches global access program for Clovis' rociletinib

28 May 2015

UK specialty pharmaceutical and services company Clinigen (LSE: CLIN) has started a global access program in Europe for Clovis Oncology’s (Nasdaq: CLVS) rociletinib, being developed to treat advanced non-small cell lung cancer.

The program is intended to allow access to rociletinib for individual named patients with advanced or metastatic epidermal growth factor receptor-mutant T790M-positive NSCLC who have previously been treated with an EGFR-targeted therapy and for whom their physician determines that there is no satisfactory alternative therapy, or rociletinib clinical trial available.

Rociletinib is an oral, mutant-selective EGFR inhibitor, currently in Phase II/III development for the treatment of NSCLC. In 2014, it was granted Breakthrough Therapy designation from the US Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK